What's New in Spondyloarthritis Dr. Arthur Kavanaugh and Dr. Eric Ruderman gave an update on what's new in axial spondyloarthritis (axSpA) at the 2026 Rheumatology Winter Clinical Symposium (RWCS) in Maui, Hawaii. https://t.co/X9MfrZLNBq https://t.co/VS04Ra5RZK

J Rheum full read editorial on What HLA-B27 Can—and Cannot—Tell Us!. HLA-B27 also holds prognostic and theragnostic value, given its association with greater structural damage, higher inflammatory burden, and better response to tumor necrosis factor and interleukin 17 inhib. https://t.co/3xNDtePEzn

RT @gibson_rheumPAC Given rising resistance, effective first-line regimens and adequate duration (14 days) are critical. PPI-based quadruple regimens remain highly effective when patients can adhere. #RNL26 https://t.co/bxqMbPFegt

RT @RichardPAConway ACR/Chest and EULAR/ERS guidelines for RA-ILD presented by Dr Sparks. I'm posting the one I use ;) #RNL26 https://t.co/fwTjB2bIqg

The vasculitis session at #RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field. https://t.co/KuVei8jiFu https://t.co/47cI4WSSkU

RT @richardPAConway Data from Scott Matson's group showing that immunosuppressing RA-ILD (agnostic to agent) results in stabilisation of the previous downward trajectory of pulmonary function tests. #RNL26 https://t.co/TMNeCsPDep

RT @RichardPAConway UIP pattern RA-ILD is where the big problem is. We are less good at treating this. Perhaps the newer agents such as nerandomilast will change this? #RNL26 https://t.co/lzKFulaomD

New studies posted this week in Arthritis & Rheumatology: Adalimumab ± MTX as first-line therapy for childhood-onset chronic uveitis https://t.co/L4QiZZBBG7 Bisphosphonates & PPI/H2RA coprescriptions in polymyalgia rheumatica https://t.co/62Pqt5Ab58 Phase 3b SOLSTICE trial: https://t.co/MsK4XC3eNh

You gotta be kidding me @mims gift link https://t.co/wf9kLhSu8a https://t.co/jB3ZYyB549

Population survey of 21 000 US adults, 62.3% reported recent use of any OTC or prescription meds. Past-7-day prevalence of any OTC medication was equal to RX med use (46%) and increased use with age among both male and female individuals. https://t.co/xeWBQ0DnlB https://t.co/c8lqXOmAaT

Early: BITE compassionate use CD19×CD3 T cell engager blinatumomab in 5 antisynthetase myositis & BCMA×CD3 teclistamab in 5 scleroderma pts, all Tx refractory. Both showed rapid clinical, serologic, histologic benefits, with cytokine release syndr as AE of concern https://t.co/CTppiWim0a

What did you miss at RheumNow Live 2026? Our Poster Hall features new data across: • Psoriatic Arthritis • Systemic Lupus Erythematosus • Lupus Nephritis • Vasculitis • Polymyalgia Rheumatica • Axial Spondyloarthritis From Phase III trials to real-world evidence, these https://t.co/vC0L04WXE3